Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2024.12.048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Echocardiographic and biomarker characteristics in diabetes, coronary artery disease or both: insights from HOMAGE trial.
Cardiovasc Diabetol
March 2025
Centre d'Investigations Cliniques Plurithématique 1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Université de Lorraine, Nancy, France.
Background: Coronary artery disease (CAD) and diabetes mellitus (DM) can induce changes in myocardial structure and function, thereby increasing the risk of heart failure (HF). We aimed to identify the alterations in echocardiographic variables and circulating biomarkers associated with DM, CAD, or both and to assess the effect of spironolactone on them.
Methods: The "Heart OMics in AGEing" (HOMAGE) trial evaluated the effect of spironolactone on circulating markers of fibrosis over 9 months of follow-up in people at risk for HF.
Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the Management of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Am J Cardiovasc Drugs
March 2025
2nd Department of Nephrology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, St. Kyriakidi 1, 54636, Thessaloniki, Greece.
Finerenone is a novel nonsteroidal mineralocorticoid receptor (MR) antagonist (MRA) with unique pharmacological properties that offer potent and selective blockade of the MR with a more favorable side effect profile than spironolactone and eplerenone. In a large phase III clinical trial involving 13,026 patients with type 2 diabetes mellitus and a broad spectrum of chronic kidney disease, finerenone provoked a substantial placebo-subtracted reduction in the risk of hospitalization for heart failure (HF). These preliminary clinical trial data, along with the ongoing uncertainty about the safety and efficacy of MR antagonism in patients with HF and higher levels of ejection fraction have provided the rationale for the design of the FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure) trial.
View Article and Find Full Text PDFUltrasound speckle tracking imaging measurement of endocardial longitudinal strain for evaluation of prognostic value of "new quadruple" therapy in patients with chronic heart failure.
Front Endocrinol (Lausanne)
March 2025
Department of Cardiology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Purpose: This study aimed to evaluate the effectiveness of the "new quadruple" therapy in chronic heart failure (CHF) patients with metabolic syndrome using 2D speckle tracking imaging (2D-STI) stratified strain imaging to measure endocardial longitudinal strain while exploring its underlying neuroendocrine mechanisms.
Patients And Methods: The study retrospectively analyzed 158 patients with heart failure with reduced ejection fraction [HFrEF; left ventricular ejection fraction (LVEF) < 40%] treated with the "new quadruple" therapy (angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, dapagliflozin, bisoprolol, and spironolactone) for 8 weeks. Conventional ultrasound indices, left ventricular global longitudinal strain (LVGLS), and subendocardial longitudinal strain (LS) were measured pre- and post-treatment.
Eplerenone vs Spironolactone and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction: A Meta-Analysis.
Mayo Clin Proc
March 2025
John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA.
In patients with acute MI, spironolactone did not reduce cardiac events at 3 y.
Ann Intern Med
March 2025
Duke University, Durham, North Carolina, USA (M.D.K., L.K.N.).
Cardiology: [Formula: see text].
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!